| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥4748.9B | ¥3368.3B | +41.0% |
| Operating Income | ¥212.4B | ¥125.5B | +69.2% |
| Ordinary Income | ¥201.5B | ¥136.2B | +48.0% |
| Net Income | ¥102.3B | ¥73.4B | +39.4% |
| ROE | 6.8% | 5.1% | - |
FY2026 Q3 cumulative results: Revenue 474.9B yen (YoY +41.0%), Operating Income 21.2B yen (+69.2%), Ordinary Income 20.2B yen (+48.0%), Net Income 10.2B yen (+39.4%). The significant revenue and profit expansion primarily reflects M&A-driven consolidation scope enlargement, notably the acquisitions of NSSK-WW (now AIN-AG1) and Francfranc during the period. Operating margin improved to 4.5% from prior year's 3.7%, demonstrating operating leverage benefits from scale expansion. However, profitability remains constrained by elevated effective tax rate of 48.2% and high goodwill concentration at 37.8% of total assets. EPS reached 291.15 yen (+38.6% YoY), while ROE stood at 6.8%, primarily supported by increased financial leverage of 3.47x rather than underlying profitability improvements.
Revenue increased 138.1B yen (+41.0% YoY) driven predominantly by M&A consolidation effects. The Dispensing Pharmacy segment recorded 405.0B yen revenue (+42.0% YoY), representing 85.3% of total revenue, while Drug and Cosmetic Store segment achieved 61.6B yen (+42.2% YoY), accounting for 13.0% of total. The parallel growth rates across segments reflect successful integration of acquired entities including Craft Corporation, Sakura Pharmacy, and other subsidiaries under NSSK-WW, plus Francfranc's retail operations. Gross profit expanded to 79.2B yen with gross margin of 16.7%, representing slight compression from implied prior margin, suggesting product mix shifts from acquired businesses. SG&A expenses increased 17.3B yen to 58.0B yen, though SG&A ratio improved to 12.2% from 12.1%, indicating scale economies are beginning to materialize. Operating income surged 8.7B yen (+69.2%) to 21.2B yen, with operating margin expanding 0.8 percentage points to 4.5%.
Non-operating items created 1.1B yen net expense versus 1.1B yen net income in prior year. Interest expense increased significantly to 1.4B yen from 0.2B yen, reflecting debt-financed acquisitions with long-term loans rising 130.0B yen to 156.5B yen. Interest coverage ratio remains adequate at 14.9x. Extraordinary items recorded net loss of 0.4B yen, including impairment loss of 0.2B yen and disposal losses of 0.4B yen, partially offset by negative goodwill gain of 0.1B yen and transfer gains. Income tax expense of 9.5B yen against profit before tax of 19.8B yen resulted in exceptionally high effective tax rate of 48.2%, substantially above standard corporate rates, compressing net income to 10.2B yen. The performance pattern represents revenue up/profit up, with top-line M&A-driven expansion translating to bottom-line growth, though profitability improvement is moderated by increased interest burden and tax efficiency challenges.
Dispensing Pharmacy segment generated 405.0B yen revenue (+42.0% YoY) with segment profit of 24.1B yen, establishing this as the core business representing 85.3% of consolidated revenue. The segment profit represents approximately 6.0% margin before corporate allocations. Drug and Cosmetic Store segment achieved 61.6B yen revenue (+42.2% YoY) with segment profit of 5.8B yen, indicating roughly 9.4% segment margin, materially higher than Pharmacy operations. Other segment recorded 8.4B yen revenue with minor profit of 0.04B yen. The 3.4 percentage point margin differential between Retail and Pharmacy segments suggests distinct business economics, with retail operations demonstrating superior unit economics despite smaller scale. Corporate allocation adjustments of negative 9.8B yen to reconcile segment profit to ordinary income reflect centralized management and system/logistics overhead expenses, representing approximately 2.1% of consolidated revenue.
[Profitability] ROE 6.8% remains below industry standards and reflects limited underlying earnings power relative to equity base, with performance primarily supported by financial leverage of 3.47x rather than operational efficiency. Operating margin 4.5% improved 0.8 percentage points from 3.7% YoY, indicating positive operating leverage from scale expansion, though absolute level remains constrained. Net profit margin 2.2% compressed from prior period due to elevated tax burden, with effective tax rate reaching 48.2% representing significant earnings quality concern. Gross margin 16.7% reflects low-margin pharmaceutical and retail business characteristics. [Efficiency] Total asset turnover 0.905x demonstrates reasonable asset utilization efficiency, while inventory turnover calculated at approximately 30 days indicates effective working capital management in pharmacy operations. Receivables turnover approximately 41 days reflects standard payment terms in dispensing pharmacy business with healthcare institutions. [Financial Health] Equity ratio 28.8% declined significantly from 45.7% prior year, reflecting debt-financed M&A strategy with long-term loans expanding to 156.5B yen. Debt-to-equity ratio 2.47x represents elevated leverage profile, while current ratio 92.4% falls below 1.0x threshold, indicating liquidity tightness with current assets 187.1B yen insufficient to cover current liabilities 202.4B yen. [Cash Position] Cash and deposits 56.7B yen covers short-term borrowings 30.8B yen by 1.84x, providing partial liquidity buffer, though working capital deficit of 15.3B yen warrants monitoring. Interest coverage 14.9x remains adequate for current debt service obligations.
Cash and deposits increased 29.8B yen from 26.9B yen to 56.7B yen, representing 110.8% growth driven primarily by debt financing activities to support M&A transactions. Working capital indicators show mixed trends with trade receivables expanding 30.8B yen to 53.1B yen (+138.0% YoY), substantially outpacing revenue growth and suggesting extended collection cycles or acquired entities' working capital characteristics. Inventories increased 12.1B yen to 47.6B yen (+34.0%), growing below revenue expansion rate and indicating inventory efficiency improvements. Trade payables surged 42.8B yen to 123.7B yen (+52.9%), reflecting effective supplier credit utilization and scale benefits in purchasing, though this contributes to negative working capital position. The 15.3B yen working capital deficit represents structural operating model characteristic in pharmacy retail where supplier payment terms exceed customer collection cycles. Short-term debt coverage from cash stands at 1.84x, providing adequate immediate liquidity cushion. The balance sheet expansion primarily reflects asset acquisitions totaling 213.9B yen increase in total assets, with goodwill rising 113.8B yen and intangible assets expanding 115.0B yen, directly attributable to NSSK-WW and Francfranc consolidations adding 121.3B yen and 41.0B yen goodwill respectively during the period.
Operating income of 21.2B yen versus ordinary income of 20.2B yen indicates net non-operating expense of 1.0B yen, primarily comprising interest expense 1.4B yen offset by interest income 0.1B yen, dividend income 0.04B yen, and other non-operating income 0.9B yen. Non-operating expense represents approximately 0.2% of revenue, consisting mainly of financing costs associated with acquisition debt, with interest burden manageable at current profitability levels. Ordinary income of 20.2B yen versus net income 10.2B yen reflects 10.0B yen reduction, decomposed as income tax expense 9.5B yen plus net extraordinary loss 0.4B yen. The 48.2% effective tax rate significantly exceeds Japan's standard corporate rate, suggesting limited deferred tax asset recognition or non-deductible expenses reducing earnings quality. Extraordinary items remain modest at 0.4B yen net loss, including impairment charges 0.2B yen and asset disposal losses 0.4B yen as non-recurring factors. Comprehensive income totaled 10.9B yen versus net income 10.2B yen, with positive 0.7B yen other comprehensive income comprising securities valuation gains 0.6B yen and hedging gains 0.2B yen, indicating fair value accounting adjustments support reported earnings modestly. The ordinary-to-operating income proximity and absence of material non-operating distortions suggest core operational earnings quality, though tax efficiency concerns warrant attention.
Full-year guidance projects revenue 646.0B yen (YoY +41.4%), operating income 28.3B yen (+67.7%), ordinary income 26.5B yen (+46.6%), with EPS forecast 384.91 yen and annual dividend 80 yen. Q3 cumulative progress rates against full-year targets stand at 73.5% for revenue, 75.1% for operating income, and 76.0% for ordinary income, all exceeding the standard 75% benchmark for nine-month period. The ahead-of-schedule progress suggests conservative full-year guidance or Q4 seasonal factors may moderate growth. Net income progress at 75.7% (10.2B versus 13.5B full-year target) aligns with ordinary income progression. No forecast revisions were implemented during Q3, indicating management confidence in achieving targets. The guidance implies Q4 revenue 171.1B yen, operating income 7.1B yen, and ordinary income 6.3B yen, representing significant sequential moderation from Q3 run rates, possibly reflecting integration costs or conservative planning. Order backlog data is not disclosed for this retail/pharmacy business model where revenue realization is immediate upon service delivery.
Annual dividend forecast of 80 yen per share represents the company's planned shareholder return, though no interim dividend was paid during Q3 (Q2 dividend per share: 0 yen). Based on full-year net income forecast of 13.5B yen and 35.1M average shares outstanding, the 80 yen dividend would represent total payout of approximately 2.8B yen, resulting in payout ratio of 20.9% against forecasted earnings. This conservative payout ratio provides substantial retained earnings for growth investment and debt reduction. Historical comparison shows prior period also recorded zero interim dividend, suggesting year-end dividend policy. No share buyback programs were disclosed during the period. Total shareholder return ratio remains equivalent to payout ratio at approximately 21% given absence of buyback activity, indicating management prioritizes reinvestment in M&A-driven expansion strategy over immediate capital returns. Dividend sustainability appears adequate given low payout ratio and growing earnings base, though cash generation quality and debt service obligations warrant monitoring given 92.4% current ratio and elevated leverage.
M&A integration and goodwill impairment risk: Goodwill totaling 198.6B yen represents 131.4% of total equity and 37.8% of total assets, with current period additions of 121.3B yen from NSSK-WW acquisition and 41.0B yen from Francfranc acquisition. Any integration failures, synergy shortfalls, or market deterioration in acquired businesses could trigger material impairment charges directly eroding shareholder equity. The concentration risk is quantitatively significant with goodwill-to-equity ratio exceeding 1.0x.
Liquidity and leverage sustainability risk: Current ratio of 92.4% indicates insufficient short-term assets to cover liabilities, with working capital deficit of 15.3B yen. Combined with debt-to-equity ratio of 2.47x and total interest-bearing debt of 187.2B yen, the financial structure presents refinancing risk if operating cash generation disappoints or credit conditions tighten. Interest coverage remains adequate at 14.9x currently but could deteriorate rapidly under adverse scenarios given low operating margins.
Segment concentration and pharmacy market regulatory risk: Dispensing Pharmacy segment represents 85.3% of revenue, creating single-segment dependency. Regulatory changes to Japan's pharmaceutical pricing system, reimbursement rate revisions by health authorities, or competitive pressure from hospital-affiliated pharmacies could materially impact profitability. The segment's 6.0% margin provides limited buffer against pricing pressures, with 1 percentage point margin decline potentially reducing operating income by approximately 20%.
[Industry Position - Retail Sector Comparison] (Reference - Proprietary Analysis)
Profitability: ROE 6.8% versus industry median 2.9% (2025-Q3, n=16), positioning above median though supported primarily by financial leverage 3.47x versus industry median 1.76x rather than superior operating returns. Operating margin 4.5% versus industry median 3.9%, placing near median and confirming competitive positioning within sector norms. Net profit margin 2.2% matches industry median 2.2% precisely, indicating representative profitability profile. Return on assets 1.9% (calculated) versus industry median 1.1%, reflecting above-median asset efficiency partially attributable to pharmacy business model characteristics.
Financial Health: Equity ratio 28.8% significantly below industry median 56.8% and well below interquartile range of 39.2%-64.5%, ranking in lower quartile and confirming elevated leverage relative to sector peers. Current ratio 92.4% substantially below industry median 1.93x and outside interquartile range of 1.48x-2.73x, representing material liquidity deficit versus sector standards. Financial leverage 3.47x significantly exceeds industry median 1.76x and upper quartile 2.55x, placing in highest leverage tier among retail peers.
Efficiency and Growth: Asset turnover 0.905x below industry median 0.95x, suggesting room for improvement in asset utilization despite pharmacy business scale. Revenue growth 41.0% YoY substantially exceeds industry median 3.0% and upper quartile 9.2%, though growth is M&A-driven rather than organic. EPS growth 38.6% YoY significantly outperforms industry median decline of 29%, reflecting successful profit expansion from acquisitions. Operating working capital and receivables/payables metrics align with typical pharmacy retail characteristics of extended supplier credit and shorter customer collection cycles.
Overall Assessment: The company demonstrates above-median revenue growth and profitability supported by aggressive M&A strategy, though financial health indicators including equity ratio and current ratio rank below sector standards, creating sustainability questions regarding the growth model's balance sheet implications.
Aggressive M&A-driven transformation creating scale but elevating financial risk profile: The 41.0% revenue expansion through NSSK-WW and Francfranc acquisitions establishes significantly larger operating platform with potential for market leadership in dispensing pharmacy segment, now representing 405.0B yen revenue base. However, goodwill concentration at 131.4% of equity and debt-to-equity reaching 2.47x creates binary outcome dependency on successful integration and synergy realization. The financial structure transition from conservative 45.7% prior equity ratio to aggressive 28.8% current ratio represents fundamental strategy shift toward leverage-driven growth.
Operating leverage beginning to emerge but margin improvement remains gradual: Operating margin expansion to 4.5% from 3.7% demonstrates scale benefits with SG&A ratio stable at 12.2%, suggesting corporate infrastructure can support larger revenue base without proportional cost increase. However, absolute margin level of 4.5% provides limited buffer against operational disruptions or competitive pressures, with industry positioning near median 3.9% confirming competitive rather than differentiated economics. The gross margin of 16.7% reflects inherent low-margin pharmaceutical distribution business model characteristics, limiting structural profitability improvement potential without fundamental business mix changes.
Liquidity tightness and working capital deficit require monitoring despite adequate interest coverage: Current ratio below 1.0x at 92.4% and negative working capital position represent near-term financial management challenges, though 1.84x cash coverage of short-term debt and 14.9x interest coverage provide operational flexibility. The trade payables increase to 123.7B yen demonstrates effective supplier credit utilization creating favorable cash conversion cycle, though sustainability depends on maintaining supplier relationships during integration period. Treasury stock holdings of 1.6B yen (292K shares) provide minor balance sheet flexibility if liquidation needed. Full-year dividend guidance of 80 yen with conservative 21% payout ratio appears sustainable from earnings perspective, contingent on cash generation meeting debt service requirements.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.